Nexstim logo

NEXSTIM PLC PUBLISHES 2016 ANNUAL REPORT

06 March 2017

Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company with a pioneering navigated non-invasive brain stimulation system, announces the publication of its 2016 Annual Report. These documents are available on the “Investor Relations” section of the Company's website at www.nexstim.com.

The Annual Report includes the Report of the Board of Directors, the Financial Statements and Consolidated Financial Statements and the Auditor's Report. A copy of the Annual Report is attached to this announcement.

 

NEXSTIM PLC

Martin Jamieson, Chairman and CEO

Further information is available on the website www.nexstim.com or by contacting:

Nexstim                                                                                                                                 +447715163942

Martin Jamieson, Chairman and CEO                                                               martin.jamieson@nexstim.com

                                                                                                                                                                                               

UB Securities Oy (Certified Adviser)                                                                                +358 (0)9 2538 0246

Citigate Dewe Rogerson                                                                                                  +44 (0)207 2821066

Katja Stout                                                                                                             katja.stout@citigatedr.co.uk

About Nexstim Plc

Nexstim is a medical technology company which has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) system for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the Company has developed a system called Navigated Brain Therapy (NBT®) which is CE-marked for chronic neuropathic pain, major depression and stroke therapy. Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com

Nexstim Plc Annual Report 2016 English.pdf

Back to Press Releases

Sorry, there are no fact sheets available. Please check back soon.

Follow us

linkedin

Twitter
YouTube